The firm aims to take advantage of rules introduced by Hong Kong’s stock exchange in April allowing listings from pre-revenue biotechs, as the bourse competes to attract startups.
The firm aims to take advantage of rules introduced by Hong Kong’s stock exchange in April allowing listings from pre-revenue biotechs, as the bourse competes to attract startups.